In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuren Pharmaceuticals Ltd.

www.neurenpharma.com

Latest From Neuren Pharmaceuticals Ltd.

Acadia, Neuren Headed To Phase III With Trofinetide In Rett Syndrome

Positive Phase II data in the unmet medical need could mean patients will have a therapy specific to their disease, rather than burdensome symptom-by-symptom treatment.

Clinical Trials Rare Diseases

Finance Watch: Moderna Launches Biggest Biopharma IPO Ever As US Market Resets Expectations

Public Company Edition: Moderna's $604m IPO launches as the US stock market is in decline and public biotechs are doing especially poorly. Also, as Shire acquisition closing moves near, Takeda firms up additional financing; and Global Blood, Theravance, Amarin capitalize on good news.

Financing Business Strategies

Deal Watch, Licensing Focus: Roche, Sanofi Exit Ongoing Anticalin Development Efforts With Pieris

Sarepta licenses gene therapy candidate from Lacerta, also makes equity investment. Neuren licenses North American rights to rare disease drug trofinetide to Acadia.

Deals Business Strategies

Zynerba Sketches Phase III Plan For Cannabinoid Gel In Fragile X

Positive Phase II study of cannabinoid ZYN002 sends stock soaring, but the trial was very small with an open-label design, and response was mostly recorded by caregivers.

Clinical Trials Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Neuren Pharmaceuticals Ltd.
  • Senior Management
  • Jon Pilcher, CFO
    Larry Glass, CSO
    James Shaw, VP, Clinical Operations
    Nancy Jones, PhD, VP, Clinical Dev.
  • Contact Info
  • Neuren Pharmaceuticals Ltd.
    Phone: (64) (3) 9092 0480
    697 Burke Rd.
    Ste. 201
    Camberwell, 3124
    Australia
Advertisement
Advertisement
UsernamePublicRestriction

Register